ReviewThe oncologist2010
Polypharmacy in older adults with cancer.
Review in The oncologist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Clinical and economic impact of medication reconciliation in cancer patients: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Comprehensive geriatric assessment prediction of postoperative complications in gastrointestinal cancer patients: a meta-analysis.Clinical interventions in aging · 2018Pooled it
- What is polypharmacy? A systematic review of definitions.BMC geriatrics · 2017Pooled it
- Senior adult oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2012Guideline
- Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment.The oncologist · 2022Trial
- Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers.Journal of geriatric oncology · 2018Trial
- Machine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugs.NPJ precision oncology · 2026Article
- Article
- Polypharmacy and quality of life in Yemeni cancer patients undergoing chemotherapy: A cross-sectional study.PLOS global public health · 2026Article
- Impact of the ONCORAL multidisciplinary city-hospital follow-up on older patients with cancer treated with oral anticancer drugs.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Nutritional Challenges in Older Cancer Patients: A Narrative Review of Assessment Tools and Management Strategies.Nutrients · 2025Review
- Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Complexity of the Therapeutic Regimen in Older Adults with Cancer: Associated Factors.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors.BMC geriatrics · 2024Observational
- Determination of drug-related problems in the hematology service: a prospective interventional study.BMC cancer · 2024Article
- Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada.Journal of pharmacy practice · 2024Article
- Development of a claims-based risk-scoring model to predict emergency department visits in older patients receiving anti-neoplastic therapy.Scientific reports · 2024Article
- Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review.Therapeutic advances in drug safety · 2024Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The definition of "polypharmacy" ranges from the use of a large number of medications; the use of potentially inappropriate medications, which can increase the risk for adverse drug events; medication underuse despite instructions to the contrary; and medication duplication. Older adults are particularly at risk because they often present with several medical conditions requiring pharmacotherapy. Cancer-related therapy adds to this risk in older adults, but few studies have been conducted in this patient population. In this review, we outline the adverse outcomes associated with polypharmacy and present polypharmacy definitions offered by the geriatrics literature. We also examine the strengths and weaknesses of these definitions and explore the relationships among these definitions and what is known about the prevalence and impact of polypharmacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.